19 January 2023 | News
The operations will begin from fourth quarter of 2023 with a capital investment of 2 billion JPY
Photo Credit: Freepik
Tokyo Headquarterd Kaneka Corporation is set to increase its GMP manufacturing capacity for mRNA in Belgium based Kaneka Eurogentec S.A.
The operations will begin from fourth quarter of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. aims to lead biopharmaceutical CDMO market for mRNA.
The use of mRNA in COVID-19 vaccines is likely to extend to other infectious diseases and therapeutics, including those for genetic disorders, cancer, etc. Pharma companies worldwide are actively developing biopharmaceutical pipelines, which will increase demand for GMP manufacturing of mRNA.